FENC · Fennec Pharmaceuticals Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-15 | Brughera Marco Maria |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
Shares sold pursuant to a 10b5-1 plan adopted on June 16, 2026. |
Common Shares
|
15,545 |
| 2026-09-15 | Brughera Marco Maria |
Director |
Convert↑
Filing footnotes — Common Shares (Direct)
Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on June 16, 2026. |
Common Shares
|
15,545 |
| 2026-09-15 | Brughera Marco Maria |
Director |
Convert↓
Filing footnotes — Stock Option (Direct)
Represents options exercised pursuant to a 10b5-1 plan adopted on June 16, 2026. |
Stock Option
|
15,545 |
| 2026-09-01 | Raykov Rosty |
Director |
Sell↓
Filing footnotes — Common shares (Direct)
Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. |
Common shares
|
10,000 |
| 2026-08-31 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-08-31 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-08-31 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-08-31 | Sayad Pierre Sargis |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Shares (Direct)
Represents sale of previously vested restricted shares and vested performance shares. |
Common Shares
|
12,000 |
| 2026-08-31 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-08-31 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-08-31 | Raykov Rosty |
Director |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024. |
Common shares
|
2,778 |
| 2026-08-28 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Convert↑
Filing footnotes — Common shares (Direct)
Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. |
Common shares
|
21,928 |
| 2026-08-28 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Convert↓
Filing footnotes — Stock Options (Direct)
Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. |
Stock Options
|
21,928 |
| 2026-08-27 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common shares (Direct)
Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). A portion of the sales proceeds from this transaction will be used by the reporting person to pay tax obligations of the reporting person. |
Common shares
|
75,000 |
| 2026-08-03 | Raykov Rosty |
Director |
Sell↓
Filing footnotes — Common shares (Direct)
Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. |
Common shares
|
10,000 |
| 2026-07-31 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-07-31 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-07-31 | Raykov Rosty |
Director |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024. |
Common shares
|
2,778 |
| 2026-07-31 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-07-31 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-07-31 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-07-01 | Raykov Rosty |
Director |
Convert↓
Filing footnotes — Stock Options (Direct)
Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Stock Options
|
15,597 |
| 2026-07-01 | Raykov Rosty |
Director |
Convert↑
Filing footnotes — Common shares (Direct)
Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
15,597 |
| 2026-07-01 | Raykov Rosty |
Director |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024. |
Common shares
|
2,778 |
| 2026-07-01 | Raykov Rosty |
Director |
Sell↓
Filing footnotes — Common shares (Direct)
Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
9,599 |
| 2026-06-30 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-06-30 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-06-30 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-06-30 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-06-30 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-06-10 | Islam Khalid |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On June 10, 2026, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant. |
Stock Option
|
25,000 |
| 2026-06-10 | Brughera Marco Maria |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On June 10, 2026, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant. |
Stock Option
|
20,000 |
| 2026-06-10 | RALLIS CHRIS A |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant. |
Stock Option
|
20,000 |
| 2026-06-10 | Cook Jodi A |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
On June 10, 2026, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant. |
Stock Options
|
20,000 |
| 2026-06-01 | Raykov Rosty |
Director |
Sell↓
Filing footnotes — Common shares (Direct)
Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
9,747 |
| 2026-06-01 | Raykov Rosty |
Director |
Convert↓
Filing footnotes — Stock Options (Direct)
Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Stock Options
|
15,597 |
| 2026-06-01 | Raykov Rosty |
Director |
Convert↑
Filing footnotes — Common shares (Direct)
Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
15,597 |
| 2026-05-31 | Sayad Pierre Sargis |
Chief Medical Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-05-31 | Raykov Rosty |
Director |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024. |
Common shares
|
2,778 |
| 2026-05-31 | Hackman Jeffrey S. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
1,159 |
| 2026-05-31 | Andrade Robert |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. |
Common shares
|
1,703 |
| 2026-05-31 | Cioffi Christiana Marie |
Chief Strategy Officer |
Award↑
Filing footnotes — Common shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common shares
|
156 |
| 2026-05-31 | Evans Terry L |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |
| 2026-05-11 | RALLIS CHRIS A |
Director |
Sell↓
Filing footnotes — Common Shares (Direct)
Shares sold to satisfy tax obligation on option exercise. |
Common Shares
|
8,346 |
| 2026-05-11 | RALLIS CHRIS A |
Director |
Convert↓
Filing footnotes — Stock Option (Direct)
Represents options exercised pursuant to a 10b5-1 plan adopted on May 19, 2025. |
Stock Option
|
14,344 |
| 2026-05-11 | RALLIS CHRIS A |
Director |
Convert↑
Filing footnotes — Common Shares (Direct)
Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on May 19, 2025. |
Common Shares
|
14,344 |
| 2026-05-01 | Raykov Rosty |
Director |
Convert↓
Filing footnotes — Stock Options (Direct)
Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Stock Options
|
15,598 |
| 2026-05-01 | Raykov Rosty |
Director |
Convert↑
Filing footnotes — Common shares (Direct)
Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
15,598 |
| 2026-05-01 | Raykov Rosty |
Director |
Sell↓
Filing footnotes — Common shares (Direct)
Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. |
Common shares
|
10,781 |
| 2026-04-30 | Sayad Pierre Sargis |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Shares (Direct)
Represents shares released from restriction from shares awarded 3/28/2025. |
Common Shares
|
168 |